Copyright
©The Author(s) 2019.
World J Hepatol. Jun 27, 2019; 11(6): 542-552
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.542
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.542
Table 1 Characteristics of the included patients
| Variable | Patients |
| n = 1912 | |
| Male gender, n (%) | 1575 (82.4) |
| Age (yr, mean ± SD) | 57(± 7.2) |
| Etiology | |
| Hepatitis C | 1369 (71.6) |
| Hepatitis B | 468 (24.5) |
| Other | 75 (3.9) |
| Albumin (g/L, mean ± SD) | 31.4(± 4.6) |
| Bilirubin [µmol/L, median (IQR)] | 24.5 (13.9-29.1) |
| Platelet count (x 109/L, mean ± SD) | 96 (± 37.4) |
| AFP [µg/L, median (IQR)] | 43 (10-184.3) |
| Tumor size [cm, median (IQR)] | 5.6 (1.8-8.4) |
| Solitary tumor, n (%) | 369 (19.3) |
| PVT | 345 (18) |
| Metastasis | 148 (7.7) |
| ECOG grade 0, n (%) | 1154 (60.4) |
| Treatment | |
| Liver resection | 67 (3.5) |
| Liver transplantation | 43 (2.3) |
| Ablative procedures (PEI, RFA and microwave) | 249 (13.1) |
| TACE | 1036 (54.1) |
| Combined treatment (TACE + ablation) | 8 (0.4) |
| Systemic therapy | 40 (2.1) |
| Conservative | 469 (24.5) |
| Overall survival, months (95%CI) | 17.9 (12.1-13.8) |
| Overall deaths, n (%) | 1219 (63.8) |
- Citation: Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol 2019; 11(6): 542-552
- URL: https://www.wjgnet.com/1948-5182/full/v11/i6/542.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i6.542